Purpose: Estimating how much of the impact of statins on coronary heart diseases (CHD), cardiovascular disease (CVD), and mortality risk is attributable to their effect on low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), and triglycerides.
effects. [9] [10] [11] [12] [13] [14] [15] [16] [17] Garnering a better understanding of the mechanisms relating statin treatment to improved outcomes has been recognized as important and might "help to elucidate the full therapeutic benefits of these agents." 14 Numerous randomized trials have reported that a larger reduction in cholesterol following statin treatment correlates with a greater reduction of CHD, CVD, and mortality risk, 6, [18] [19] [20] [21] [22] [23] thus suggesting a mediation effect. However, typical trials where only the treatment is randomized are susceptible to yield biased estimates of the importance of intermediate pathways, unless appropriate control is made for potential confounders and causal mediation analyses are conducted. 24 We are aware of only 1 study that used such causal mediation methods to quantify the importance of the cholesterol pathway in the effect of statins. 25 The aim of the current study is to provide further evidence concerning the importance of lipid-related pathways in the effect of statins on CHD, CVD, and mortality risks using causal mediation methods. More specifically, we investigated how much of the total effect of statins on the 5-year risk of CHD is attributable to their effect on (1) LDL, (2) HDL, and (3) triglycerides, and similarly for 5-year risk of CVD and all-cause mortality. This 5-year period was chosen for comparability with previous studies whose average follow-up time is often approximately 5 years. To perform this mediation analysis, we propose a g-formula estimator that directly accounts for censored time to events and provides results on scales that are easy to interpret.
| METHODS

| Data
We used data from the Multi-Ethnic Study of Atherosclerosis (MESA), 
| Study design
We analyzed the data from our observational cohort as if they arose from a sequence of 4 nonrandomized "trials," where each subject could participate in more than 1 trial. 39 This approach seeks to emulate the randomized trial gold-standard utilizing observational data in the design of the study and thus offers greater comparability to the results of randomized trials. Figure 1 depicts Although the cholesterol mediator and the statin exposure were measured simultaneously, the beginning of the statin exposure precedes the cholesterol measurement because it corresponds to medications that the subjects were taking prior to their entry examination. Follow-up for CHD, CVD, and death events started at the date of entry into the trial. Trials 2, 3, and 4 were constructed similarly, respectively, having their entry examination at MESA's Exams 3, 4, and 5, and having their pre-entry examination at MESA's Exams 2, 3, and 4. Note that already being a participant in a previous trial does not automatically preclude a subject from being eligible in another trial. Thus, for example, a given subject could simultaneously contribute follow-up information to all 4 trials if they remained CVD free and were not statin users throughout all preentry examinations.
| CHD, CVD, and all-cause mortality
All-cause mortality as well as CHD and CVD events have been monitored for all participants from cohort entry until the end of 2013 utilizing multiple sources of information. CHD included myocardial infarction, resuscitated cardiac arrest, definite angina, probable angina followed by revascularization and CHD death. In addition to any CHD event, CVD also included stroke, stroke death, other atherosclerotic death, and other CVD death. For more information, see the Appendix of reference.
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KEY POINTS
• Few previous studies have attempted quantifying the relative importance of the lipid pathways in the effect of statins on coronary heart diseases, cardiovascular diseases, and mortality using appropriate causal mediation approaches.
• In this study, the effect of statins on coronary heart disease, cardiovascular disease, and mortality appeared to be independent of their effect on high-density lipoprotein cholesterol and triglycerides.
• The preventive effect of statins on coronary heart diseases could be attributed in large part to their effect on LDL.
• The g-formula estimator we proposed is a promising approach to elucidate intermediate pathways for other drug classes
| LDL, HDL, and triglycerides
Blood samples were obtained at all examinations and were assayed for HDL and triglycerides. LDL was estimated using Friedewald equation. 28 
| Statins
The use of statins was determined by questionnaire. The participants were also asked to bring containers for all medications used in the 2 weeks preceding each examination. 
| Potential confounders
A rich set of 16 potential confounders was selected a priori (seeTable 1). and then up to 3 more times (average = 1.5 times). All other covariates
were measured at every examination.
| Statistical analyses
We describe in more detail the analyses that were performed to We consider the potential outcome framework to causal inference to define the quantities we targeted. 33 To simplify the presentation, We also considered the previous quantities on a relative risk reduction (RRR) scale, dividing by the negative of the baseline risk, −E Y 0M0 ½ .
| Intention to treat estimation
We first describe the analyses we conducted to obtain an observational study equivalent of intention to treat estimates where statins initiators are compared with non-initiators, regardless of whether they remained adherent to their initial treatment (taking statins or not taking statins) in follow-up visits.
We propose a semi-parametric g-formula estimator of the total effect and its components. Our estimator shares similarities with the approach of Imai et al. 35 Details of the development of our estimator are provided in Appendix 1, and simulation studies investigating its performance are presented in Appendix 2.
Letting C be the potential confounders in Table 1 and c i, t be the observed values for subject i in trial t, we propose the following esti-
when a = a * and
when a ≠ a * , where N = n 2 + n 3 + n 4 + n 5 . Assumptions of the models were visually verified and appeared reasonable for most of the range of the data. Confidence intervals (CI) were obtained through the percentile method by performing non-parametric bootstrap with 2000 resamples. 38 The bootstrap samples were taken from the original dataset to account for the within- subject correlation arising from the fact that each subject could participate in more than 1 trial.
| Adherence-adjusted estimation
Intention to treat estimates can be problematic because they depend on the proportion of the subjects who adhere to their initial treatment. 39 We thus consider an adherence-adjusted analysis as our primary analysis. Our approach for obtaining adherence-adjusted estimates essentially consisted in discarding information on follow-up visits once a subject discontinued their initial treatment and using inverse probability weighting to redistribute the weights of such subjects onto similar subjects that pursued their initial treatment. More details are provided in Appendix 3.
| Sensitivity analyses
We conducted an adherence-adjusted analysis comparing Atorvastatin (the most commonly used statin in our data) users to non-statin users to investigate if the decomposition of the effect might vary according to type of statins. We have also performed 2 sensitivity analyses where alcohol consumption (yes or no) and self-reported walking pace (in 5 categories ranging from very slow to brisk), as a measure of physical activity, 40 were considered as additional confounders. These are considered as sensitivity rather than main analyses because of the amount of missing data on these variables (≈10% for alcohol, walking pace was not collected at Exam 4). Sensitivity analyses yielded similar results to those presented below (see Appendix 4).
| Missing data
A single Expectation-Maximization imputation of missing Agatston scores was performed (correlations between 0.86 and 0.99 were observed between measures taken at Exam 1 and measures taken at other Exams, not presented). Otherwise, only rows without any missing data were considered. Available data are described in Figure 2 .
| RESULTS
Pre-entry characteristics of the participants in the trials are reported in Table 1 (characteristics by trial 
| DISCUSSION
Our results provide evidence of the importance of the LDL-lowering properties of statins on reducing the risk of CHD. In fact, our indirect effect estimate is larger than the total effect estimate. This suggests that statins decrease the risk of CHD because of their LDL-lowering properties, but slightly increase the risk through other pathways; the net effect remaining beneficial. Our study also provides evidence that the HDL and triglycerides pathways play a minor role in the effect of statins on CHD, CVD, and mortality. Regarding the importance of the LDL pathway on CVD or mortality, our study is somewhat inconclusive: small indirect associations were observed, but wide CI were
obtained. An expanded discussion of the substantive results is provided in Appendix 7.
It is important to take into account a number of potential limitations when interpreting our results. First, because we considered observational data, any causal inference made rests upon the assumptions of no unmeasured confounding. Because we considered a rich set of potential confounders, which was built based on substantive knowledge, it appears reasonable to assume that the most important confounding factors were accounted for. Moreover, our total effect estimates are consistent with those produced by large meta-analyses of randomized controlled trials.
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The validity of our results also relies on the assumptions of the models that were used to construct our g-formula estimator, such as the proportional hazard assumption of the Cox model. These assumptions were visually verified and appeared to be reasonable.
Some bias could have been introduced by our treatment of missing data. A better alternative might have been to perform multiple imputations. 41 However, this option was thought to be impractical to implement, due to the computational burden of combining bootstrapping with multiple imputations.
Although we know that the initiation of our statin exposure precedes the measure of the cholesterol mediators, we do not know the precise time when initiation occurred. Some bias could arise if the delay between initiation and measurement of the cholesterol mediator is too short in some cases for the full impact of statin treatment on cholesterol to be realized. However, the mean LDL reduction associated with statin treatment we observed was very close to the one reported in a large meta-analysis of randomized trials (0.93 mmol/L vs 1.00 mmol/L-analysis not presented), 5 which suggests that this bias might be small.
Our adherence-adjusted analysis attempted to correct for the misclassification that occurs when a user becomes a non-user or viceversa. However, the exact time where switching occurs is unknown.
Therefore, some individuals have contributed follow-up time for outcome events in the wrong exposure group before being censored, which is likely to have biased our effect estimates towards the null. The total estimated effect is decomposed in an indirect effect, due to the effect of statins on a given mediator, and a direct component, not due to the effect of statins on that given mediator.
Abbreviations: CHD, coronary heart diseases; CVD, cardiovascular diseases; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RD, risk difference; RRR, relative risk reduction; Trig., triglycerides.
Estimates are adjusted for age, education, gender, health insurance, race/ethnicity, Field Center, previous LDL, previous HDL, previous triglycerides, Agatston score, BMI, cigarette smoking, diabetes, family history of CVD, hypertension, and total number of medication.
Because the adherence proportion after 1 visit is high (84%) and because our total effect point estimates are consistent with previous findings, we hypothesize that this misclassification bias may be small.
Moreover, our analysis only investigated the contribution of statins through short-term changes in cholesterol, not accounting for how cholesterol varies over time. This is similar to the approach used in many clinical trials where the reduction in cardiovascular events is correlated with the reduction in cholesterol after 1 or 2 years. 6, 20, 23 It is nonetheless possible that the indirect effect of statins on cardiovascular outcomes through cholesterol depends both on short-and long-term effects on cholesterol. Recently, a parametric and a semiparametric g-formula approach have been proposed to perform mediation analysis with time-varying exposures and mediators and could be considered to provide further insights on the mechanism relating statin to better cardiovascular outcomes. 42, 43 However, accounting for the time-varying nature of the variables comes at the cost of adding further complexities to the analysis. For instance, the parametric g-formula approach of Lin et al 42 depends on more stringent assumptions than ours, such as the correct parametric specification of the joint distribution of the exposure and confounders at each time-point whereas our method uses a non-parametric estimator for the joint distribution of the confounders. While the semi-parametric method of
VanderWeele and Tchetgen Tchetgen 43 avoids making such assumptions, it is potentially unstable in certain circumstances. 43 Our study also has a number of noteworthy strengths. The generalizability of the results to the American population is improved by the fact that we used data from a multi-ethnic population-based cohort with participants from multiple centers across the United States. The large number of participants, the length of the follow-up period and the relatively small number of losses-to-follow-up for a study of that length should also be noted. From a methodological perspective, we believe that our semi-parametric g-formula estimator is a promising approach to help elucidate intermediate pathways, because it has the ability of directly accounting for censored time to events through the use of the Cox model and avoids relying on stringent parametric assumptions. It also provides estimates on RD or RRR scales that are easy to interpret. Our approach is of particular interest for investigating exposure effects attributable to intermediate pathways in a relatively specific time frame, such as short-term effects on the mediator.
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